Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Carpenter

Showing results (21-30 of 62) with videos related to

Pageof 7
Sort By:
BMJ (Clinical Research Ed.)|January 21, 2014
Assessment of US pathway for approving medical devices for rare conditionsThomas J Hwang, Daniel Carpenter, Aaron S Kesselheim
Science Translational Medicine|February 27, 2015
Paying for innovation: reimbursement incentives for antibioticsThomas J Hwang, Daniel Carpenter, Aaron S Kesselheim
Tobacco Control|August 6, 2017
Tobacco industry response to a ban on lights descriptors on cigarette packaging and population outcomesHillel R Alpert, Daniel Carpenter, Gregory N Connolly
Science (New York, N.Y.)|May 31, 2014
Target small firms for antibiotic innovationThomas J Hwang, Daniel Carpenter, Aaron S Kesselheim
Foot & Ankle Orthopaedics|January 31, 2022
Clinical Outcomes and Cadaveric Biomechanical Analysis of Endoscopic Percutaneous Achilles Tendon Rupture Repair With Absorbable SutureDaniel Carpenter, Katherine Dederer, Paul Weinhold, et al.
The Journal of Clinical Psychiatry|December 3, 2003
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summaryJohn M Kane, Stefan Leucht, Daniel Carpenter, et al.
BMJ Open|March 4, 2019
Effect of the public disclosure of industry payments information on patients: results from a population-based natural experimentGenevieve P Kanter, Daniel Carpenter, Lisa Lehmann, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 23, 2003
Expert consensus-based medication-use evaluation criteria for atypical antipsychotic drugsRaymond C Love, Marie Mackowick, Daniel Carpenter, et al.
Health Affairs (Project Hope)|October 28, 2004
Approval times for new drugs: does the source of funding for FDA staff matter?Daniel Carpenter, Michael Chernew, Dean G Smith, et al.
American Journal of Public Health|April 21, 2010
US pharmaceutical innovation in an international contextSalomeh Keyhani, Steven Wang, Paul Hebert, et al.
Pageof 7

Showing results (21-30 of 62) with videos related to

Sort By:
Pageof 7
BMJ (Clinical Research Ed.)|January 21, 2014
Assessment of US pathway for approving medical devices for rare conditionsThomas J Hwang, Daniel Carpenter, Aaron S Kesselheim
Science Translational Medicine|February 27, 2015
Paying for innovation: reimbursement incentives for antibioticsThomas J Hwang, Daniel Carpenter, Aaron S Kesselheim
Tobacco Control|August 6, 2017
Tobacco industry response to a ban on lights descriptors on cigarette packaging and population outcomesHillel R Alpert, Daniel Carpenter, Gregory N Connolly
Science (New York, N.Y.)|May 31, 2014
Target small firms for antibiotic innovationThomas J Hwang, Daniel Carpenter, Aaron S Kesselheim
Foot & Ankle Orthopaedics|January 31, 2022
Clinical Outcomes and Cadaveric Biomechanical Analysis of Endoscopic Percutaneous Achilles Tendon Rupture Repair With Absorbable SutureDaniel Carpenter, Katherine Dederer, Paul Weinhold, et al.
The Journal of Clinical Psychiatry|December 3, 2003
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summaryJohn M Kane, Stefan Leucht, Daniel Carpenter, et al.
BMJ Open|March 4, 2019
Effect of the public disclosure of industry payments information on patients: results from a population-based natural experimentGenevieve P Kanter, Daniel Carpenter, Lisa Lehmann, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 23, 2003
Expert consensus-based medication-use evaluation criteria for atypical antipsychotic drugsRaymond C Love, Marie Mackowick, Daniel Carpenter, et al.
Health Affairs (Project Hope)|October 28, 2004
Approval times for new drugs: does the source of funding for FDA staff matter?Daniel Carpenter, Michael Chernew, Dean G Smith, et al.
American Journal of Public Health|April 21, 2010
US pharmaceutical innovation in an international contextSalomeh Keyhani, Steven Wang, Paul Hebert, et al.
Pageof 7